Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights.
Josep Ramon MarsalIratxe Urreta-BarallobreMarimar Ubeda-CarrilloDimelza OsorioBlanca LumbrerasDavid LoraBorja M Fernández-FelixGerard OristrellEduard Ródenas-AlesinaLorena HerradorMónica BallesterosJavier ZamoraJose I PijoanAida RiberaIgnacio Ferreira-GonzálezPublished in: Trials (2022)
The DoA between death and AMI is highly variable and may lead to a considerable SSR variation in a trial including MACE.